Running title: The cancer stem cell marker CD44 promotes bone metastases Keywords: CD44, bone metastases, cancer stem cells, hyaluronan, osteoclasts 2 Abstract CD44, an adhesion molecule that binds to the extracellular matrix, primarily to hyaluronan (HA), has been implicated in cancer cell migration, invasion, and metastasis. CD44 has also recently been recognized as a marker for stem cells of several types of cancer. However, the roles of CD44 in the development of bone metastasis are unclear. Here, we addressed this issue by using bone metastatic cancer cell lines, in which CD44 was stably knocked down.
Introduction
CD44, a single-chain, single-pass, transmembrane glycoprotein, is a major adhesion molecule for the extracellular matrix that binds primarily to the extracellular glycosaminoglycan hyaluronan (HA) (1, 2) . CD44 has been implicated in a wide variety of physiological processes, including leukocyte homing and activation, wound healing, and cell migration as well as tumor cell migration, invasion, and metastasis. CD44 has also been recently recognized as one of the cell surface markers associated with cancer stem cells (CSCs), also referred to as cancer-initiating cells, in several types of cancers (2, 3) .
Although the nature of CSCs is still controversial, CD44-expressing subfractions of many human carcinomas are highly malignant and share common properties with CSCs. CD44-positive CSC-like cells have been shown to possess enhanced ability for metastasis (4, 5).
Mandal et al. showed that the inhibitory effects of simvastain and fish oil on bone metastasis are associated with the reduced expression of CD44 (6, 7). Furthermore, clinical studies have suggested a positive correlation between CD44 expression and bone metastasis (8, 9).
These findings suggest that CD44 has roles in the development of bone metastasis; however, the underlying mechanisms are unclear.
HA, a ubiquitous extracellular and cell surface-associated matrix, is a high-molecular-weight linear glycosaminoglycan composed of repeating disaccharides of glucuronic acid and Nacetylglucosamine (10). HA synthesis and degradation are regulated by the enzymes HA synthases (HASs) and hyaluronidases, respectively (10). Three isoforms of HAS, HAS1, HAS2, and HAS3, and 6 associated genes for hyaluronidases have been identified thus far.
HA concentrations are usually elevated in malignant tumors compared with corresponding benign or normal tissues and are negatively correlated with clinical outcomes (11, 12). HA has also been shown to promote proliferation, invasion, and metastasis of cancer cells (10-12).
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WST-1 (Roche Diagnostics K.K., Tokyo, Japan) according to the manufacturer's protocol.
The absorbance was measured using a microplate reader (Nippon Bio-Rad Laboratories, Tokyo, Japan) at a wavelength of 450 nm. Each assay was performed in quadruplicate and repeated at least three times.
Tumor sphere formation
Tumor sphere formation assays were performed as described previously (16) . After culture, the number of tumor spheres of >100 μm in diameter was counted by light microscopy. Data are expressed as the number of tumor spheres/well. Each assay was performed in triplicate and repeated at least three times.
Wound healing assay
The cells (1 × 10 5 cells/well) were plated in growth medium in 24-well plates and incubated for 24 hours. After confirming the formation of a complete monolayer, the cells were wounded by scratching lines with a standard 200-μl plastic tip. Migration and cell movement throughout the wound area was observed with a phase-contrast microscope after 24 or 48
hours. The percentage of filled wound area was calculated as follows: filled wound area (%) = (original wound area − remaining wound area)/original wound area × 100. Each assay was performed in triplicate and repeated at least three times.
Cell invasion assay
Cell invasion assays were performed using 24-well BD Biocoat Matrigel Invasion Chambers 
Osteoclast differentiation in vitro
Osteoclast differentiation was examined using mouse bone marrow cultures, as described previously (17) . In brief, bone marrow cells harvested from ddY mice (male, 4 weeks old;
Japan SLC, Shizuoka, Japan) were cultured in α-minimum essential medium (αMEM; Life Technologies Japan Ltd.) supplemented with 10% FBS in the presence or absence of 4-MU (0.01-0.3 mM) for 6 days. Osteoclast differentiation was induced by 10 μM prostaglandin E2 (PGE2; Cayman Chemical Company, Ann Arbor, MI) or 50 ng/ml macrophage colonystimulating factor (M-CSF; Kyowa Hakko Kogyo Co., Tokyo, Japan) and 100 ng/ml receptor activator of NF-κB ligand (RANKL; PeproTech EC, London, UK). After culture, the cells were stained with tartrate-resistant acid phosphatase (TRAP) using a commercial kit (SigmaAldrich). The TRAP-positive multinucleated (≥3 nuclei) cells in each well were counted by light microscopy. Data are expressed as the number of osteoclasts/well. Each assay was performed in quadruplicate and repeated at least three times.
Microarray analysis
Total RNA was extracted using a High Pure RNA Isolation Kit (Roche Diagnostics K.K.). The
RNAs were subjected to microarray full service (Hokkaido System Science Co., Ltd., Hokkaido, Japan) and assessed using a Whole Human Genome Oligo Microarray Kit Ver2.0
GeneChip (Agilent Technologies, Inc., Santa Clara, CA). Microarray data were deposited at the National Center for Biotechnology Information Gene Expression Omnibus with the accession number GSE45613.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
RT-PCR was performed as described previously (17) . Primer sequences were as follows: (18) . The sizes of the fragments were confirmed by reference to a 100-bp DNA ladder.
Real-time RT-PCR
Real-time RT-PCR was performed using a One
Step SYBR PrimeScript PLUS RT-PCR Kit (Takara Bio Inc.) with a StepOnePlus Real-Time PCR system (Life Technologies Japan Ltd. 
Animal experiments
Tumor formation in the orthotopic sites and metastases to bone and lung were determined, as described previously (17, 19) . was administered daily by oral gavage from days 1-27, and mice were sacrificed on day 28 (20) . All animal experiments were reviewed by the Animal Management Committee of Matsumoto Dental University.
Histological and histomorphometric analyses
Paraffin sections were prepared by conventional methods. Histomorphometric analysis of the tumor burden in bone and lung and the number of osteoclasts at the tumor-bone interface was performed as described previously (17, 19) . Data are expressed as tumor area (mm 2 ), tumor area/total area (%), and the number of osteoclasts/mm bone surface (N. Oc/BS), respectively.
Immunohistochemistry and immunofluorescence
Immunohistochemistry: Immunohistochemical staining for CD44 was performed using a Histofine Simple Stain Kit (Nichirei Biosciences Inc., Tokyo, Japan) according to the manufacturer's protocol. Chromogen was developed using a DAB Liquid System (Dako Japan Inc., Kyoto, Japan). The slides were counterstained with hematoxylin.
Immunofluorescence: Immunofluorescence staining for CD44 and HA was performed as described previously (21). Cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI).
Statistical analysis
Data are expressed as mean ± SEM. The data were analyzed by one-way ANOVA followed by Tukey-Kramer tests for determining differences between the groups. Student's t-test was performed for comparing two groups. P values of <0.05 were considered significant. 
Results

Expression of CD44 in bone metastatic cancer cell lines
We firstly examined CD44 expression in human cancer cell lines. Flow cytometric analysis demonstrated that CD44 was highly expressed in MDA-MB-231, A375, PC-3, and HARA-B cells (Supplementary Figure S1A -D) , all of which have been shown to frequently metastasize to bone when inoculated into mice (17, (22) (23) (24) . MCF-7 cells, which possess less bone metastatic potential (25), showed lower CD44 expression (Supplementary Figure S1E) .
Effects of CD44 knockdown on cancer cells in vitro
To examine the roles of CD44 in cancer metastasis, we established MDA-MB-231 human breast cancer and A375 human melanoma cell clones stably expressing shRNA against CD44 (MDA/shCD44 and A375/shCD44). Flow cytometry confirmed that CD44 knockdown markedly decreased CD44 expression (Supplementary Figure S2A 
Effects of CD44 knockdown on tumorigenic and metastatic potential of cancer cells in nude mice
Next, we examined the effects of CD44 knockdown on tumorigenicity and metastasis in vivo.
Tumor formation in the orthotopic mammary fat pad was markedly inhibited in mice injected with MDA/shCD44 clones compared with those injected with the control cells ( Figure 2A ). 
Effects of the HA synthesis inhibitor on bone metastasis
The involvement of the CD44-HA axis in the development of bone metastasis was finally 
Discussion
CD44 has been implicated in various cancer phenotypes, including enhanced cell proliferation, migration, invasion, and metastasis (2) . Consistent with this, our results showed that CD44 knockdown in cancer cells suppressed cell migration and invasion in vitro and that CD44 overexpression increased migration and invasion. This suggests that CD44 increases bone metastasis by enhancing migration and invasion of cancer cells. However, it is unlikely that these metastasis-promoting effects are specific for bone metastasis. In fact, lung metastasis was also reduced in MDA/shCD44 clones (Supplementary Figure S8) .
We previously demonstrated that CD44 is expressed on osteoclasts and their precursor cells These results suggest that the CD44-HA interaction plays a critical role in stem cell homing to bone marrow. Since HA has also been identified as a component of the cancer stem cell niche (11), it is possible that the CD44-HA interaction facilitates tumor cell arrest and colonization in bone, leading to an increase in the development of bone metastases.
In the present study, microarray analysis revealed that CD44 knockdown downregulates HAS2 mRNA expression, leading to the reduction in HA production. It has also been shown that downregulation of HAS2 reduces CD44 expression in cancer cells (36, 37). Furthermore, consistent with a previous report (38), we showed that the inhibition of HASs by 4-MU suppresses CD44 expression. It is possible that there is a reciprocal regulatory mechanism for the expression of CD44 and HAS2, although the precise mechanism is yet to be determined. On the other hand, HAS3 expression was not affected both by CD44 knockdown and 4-MU treatment in MDA-MB-231 and A375 cells, which has also been reported in other Figure S10) , suggesting that CD44s, but not CD44v, made a major contribution to the development of bone metastasis.
In conclusion, our results suggest that CD44 expression in cancer cells contributes to the promotion of bone metastases by enhancing tumorigenicity, cell migration and invasion, and HA production. Our results also suggest the possible involvement of CD44-expressing cancer stem cells in the development of bone metastases. Therefore, disruption of CD44-HA interaction is a potential target for therapeutic intervention for bone metastases. 
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